Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Calcineurin inhibitors; Corticosteroids
  • Indications Prurigo nodularis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY-PN PRIME; PRIME
  • Sponsors Sanofi; Sanofi-Aventis GmbH

    • Most Recent Events

    • 01 May 2023 Results of pooled analysis (from two studies NCT04183335 and NCT04202679) assessing the effect of Dupilumab in patients with prurigo nodularis published in the Nature Medicine
    • 21 Mar 2023 Results of pooled analysis from LIBERTY PN-PRIME and PRIME2, assessing proportion of patients achieving clinically meaningful improvement in these scores , presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of pooled analysis ((N=311 from two studies NCT04183335/NCT04202679) assessing the psychometric properties of Sleep-NRS in adult patients with prurigo nodularis presented at the American Academy of Dermatology annual Meeting 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top